MD4615C1 - Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine - Google Patents

Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine Download PDF

Info

Publication number
MD4615C1
MD4615C1 MDA20140122A MD20140122A MD4615C1 MD 4615 C1 MD4615 C1 MD 4615C1 MD A20140122 A MDA20140122 A MD A20140122A MD 20140122 A MD20140122 A MD 20140122A MD 4615 C1 MD4615 C1 MD 4615C1
Authority
MD
Moldova
Prior art keywords
making
isolated solid
pharmaceutical composition
dosage form
solid form
Prior art date
Application number
MDA20140122A
Other languages
English (en)
Romanian (ro)
Russian (ru)
Other versions
MD20140122A2 (ro
MD4615B1 (ro
Inventor
Син-Ицу КУВАБЭ
Такэхико ЯНАГИМА-ТИ
Хидэюки ЁСИЯМА
Симон ПАЙНС (покойный)
ГРУТ Элинор ДЕ
РУБИО Силвина ГАРСИЯ
Питер Манини
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4615(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MD20140122A2 publication Critical patent/MD20140122A2/ro
Publication of MD4615B1 publication Critical patent/MD4615B1/ro
Publication of MD4615C1 publication Critical patent/MD4615C1/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MDA20140122A 2012-04-20 2013-04-18 Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine MD4615C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636108P 2012-04-20 2012-04-20
PCT/US2013/037159 WO2013158874A1 (en) 2012-04-20 2013-04-18 Methods of producing anamorelin hydrochloride having controlled chloride content

Publications (3)

Publication Number Publication Date
MD20140122A2 MD20140122A2 (ro) 2015-05-31
MD4615B1 MD4615B1 (ro) 2019-01-31
MD4615C1 true MD4615C1 (ro) 2019-08-31

Family

ID=48225135

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140122A MD4615C1 (ro) 2012-04-20 2013-04-18 Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine

Country Status (48)

Country Link
US (8) US20140018391A1 (https=)
EP (3) EP2838892B1 (https=)
JP (3) JP6109925B2 (https=)
KR (2) KR102141323B1 (https=)
CN (3) CN110041304A (https=)
AP (1) AP2014008013A0 (https=)
AR (1) AR090725A1 (https=)
AU (1) AU2013249197B2 (https=)
BR (1) BR112014025972A8 (https=)
CA (2) CA2869893C (https=)
CL (1) CL2014002817A1 (https=)
CO (1) CO7131356A2 (https=)
CR (1) CR20140530A (https=)
CY (1) CY1120276T1 (https=)
DK (2) DK3517532T3 (https=)
DO (1) DOP2014000235A (https=)
EA (1) EA031581B1 (https=)
EC (1) ECSP14027739A (https=)
ES (2) ES2658862T3 (https=)
GE (2) GEP20186902B (https=)
HK (1) HK1248694A1 (https=)
HR (1) HRP20180316T1 (https=)
HU (2) HUE050865T2 (https=)
IL (1) IL235064B (https=)
JO (1) JO3353B1 (https=)
LT (1) LT2838892T (https=)
MA (1) MA37524B1 (https=)
MD (1) MD4615C1 (https=)
ME (1) ME02966B (https=)
MX (1) MX354793B (https=)
MY (1) MY170068A (https=)
NI (1) NI201400124A (https=)
NO (1) NO2877697T3 (https=)
NZ (1) NZ700833A (https=)
PE (1) PE20150084A1 (https=)
PH (1) PH12014502351A1 (https=)
PL (2) PL2838892T3 (https=)
PT (2) PT3517532T (https=)
PY (1) PY1316881A (https=)
RS (1) RS56869B1 (https=)
SG (2) SG10201608488RA (https=)
SI (2) SI3290410T1 (https=)
TN (1) TN2014000421A1 (https=)
TW (2) TWI677494B (https=)
UA (1) UA116207C2 (https=)
UY (1) UY34753A (https=)
WO (1) WO2013158874A1 (https=)
ZA (1) ZA201408508B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
GEP20186939B (en) * 2014-09-04 2018-12-25 Healthcare Sa Helsinn Medical treatments based on anamorelin
EP3954369B1 (en) 2015-07-24 2025-08-20 Lumos Pharma, Inc. Salts and prodrugs of 1-methyl-d-tryptophan
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
BR112022002767A2 (pt) * 2019-08-30 2022-05-10 Helsinn Healthcare Sa Métodos de fabricação de um comprimido de cloridrato de anamorelina, comprimidos e método para melhorar um ou mais sintomas de caquexia de câncer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
CN1882526A (zh) * 2003-09-26 2006-12-20 兰贝克赛实验室有限公司 制备伏格列波糖的方法
CN1976921B (zh) 2004-06-29 2013-08-21 蓝宝石治疗公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形
WO2008100448A2 (en) 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Also Published As

Publication number Publication date
CN110041398A (zh) 2019-07-23
US20190000914A1 (en) 2019-01-03
PT3517532T (pt) 2021-11-08
CA2869893A1 (en) 2013-10-24
IL235064A0 (en) 2014-12-31
KR20190044697A (ko) 2019-04-30
BR112014025972A8 (pt) 2021-06-22
US10300105B2 (en) 2019-05-28
UY34753A (es) 2013-11-29
JP2018076375A (ja) 2018-05-17
US20150072934A1 (en) 2015-03-12
TW201722928A (zh) 2017-07-01
HUE050865T2 (hu) 2021-01-28
UA116207C2 (uk) 2018-02-26
KR20150013115A (ko) 2015-02-04
HK1202863A1 (en) 2015-10-09
PH12014502351B1 (en) 2015-01-12
CY1120276T1 (el) 2019-07-10
HK1248694A1 (en) 2018-10-19
PY1316881A (es) 2016-06-01
KR102141323B1 (ko) 2020-08-05
US20190231843A1 (en) 2019-08-01
RS56869B1 (sr) 2018-04-30
US10905737B2 (en) 2021-02-02
AU2013249197A1 (en) 2014-10-30
US9872883B2 (en) 2018-01-23
JP6109925B2 (ja) 2017-04-05
MA37524A1 (fr) 2016-06-30
CA3031652C (en) 2020-10-27
DK3517532T3 (da) 2022-01-03
CL2014002817A1 (es) 2015-08-14
US9981002B2 (en) 2018-05-29
ME02966B (me) 2018-07-20
TWI677494B (zh) 2019-11-21
EP3517532B1 (en) 2021-10-13
DOP2014000235A (es) 2015-01-31
WO2013158874A1 (en) 2013-10-24
TWI589572B (zh) 2017-07-01
EP3290410B1 (en) 2020-07-01
CN103857669A (zh) 2014-06-11
AU2013249197B2 (en) 2017-04-06
NZ700833A (en) 2016-01-29
EA031581B1 (ru) 2019-01-31
CA2869893C (en) 2019-03-05
TW201348224A (zh) 2013-12-01
EP3517532A1 (en) 2019-07-31
KR101972998B1 (ko) 2019-04-29
HRP20180316T1 (hr) 2018-04-06
SG11201406478XA (en) 2014-11-27
AR090725A1 (es) 2014-12-03
MY170068A (en) 2019-07-03
NO2877697T3 (https=) 2018-10-13
CA3031652A1 (en) 2013-10-24
US20160237115A1 (en) 2016-08-18
IL235064B (en) 2019-09-26
NI201400124A (es) 2015-09-21
JP6284665B2 (ja) 2018-02-28
PL3290410T3 (pl) 2021-01-11
PE20150084A1 (es) 2015-01-23
SI3290410T1 (sl) 2020-11-30
ZA201408508B (en) 2020-01-29
CN110041304A (zh) 2019-07-23
GEP20186902B (en) 2018-10-25
CN103857669B (zh) 2019-06-28
SI2838892T1 (en) 2018-05-31
US20140018391A1 (en) 2014-01-16
AP2014008013A0 (en) 2014-10-31
JP2017101082A (ja) 2017-06-08
US20160229889A1 (en) 2016-08-11
ES2658862T3 (es) 2018-03-12
HUE035697T2 (en) 2018-05-28
DK2838892T3 (en) 2018-03-12
MD20140122A2 (ro) 2015-05-31
JP2015514779A (ja) 2015-05-21
SG10201608488RA (en) 2016-12-29
MA37524B1 (fr) 2017-04-28
MD4615B1 (ro) 2019-01-31
PL2838892T3 (pl) 2018-05-30
JP6616853B2 (ja) 2019-12-04
MX354793B (es) 2018-03-21
ES2820354T3 (es) 2021-04-20
GEAP201813634A (en) 2018-06-25
TN2014000421A1 (en) 2016-03-30
BR112014025972A2 (pt) 2017-06-27
LT2838892T (lt) 2018-03-12
PT2838892T (pt) 2018-02-28
EP2838892B1 (en) 2017-12-06
CR20140530A (es) 2015-03-25
EP3290410A1 (en) 2018-03-07
ECSP14027739A (es) 2015-12-31
US9956261B2 (en) 2018-05-01
US10576122B2 (en) 2020-03-03
EA201401151A1 (ru) 2015-06-30
JO3353B1 (ar) 2019-03-13
US9403867B2 (en) 2016-08-02
EP2838892A1 (en) 2015-02-25
US20160235804A1 (en) 2016-08-18
CO7131356A2 (es) 2014-12-01
PH12014502351A1 (en) 2015-01-12
MX2014012178A (es) 2015-08-05
US20200276259A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
NZ716487A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
BR112015027055A8 (pt) bi-heteroarilas, usos das mesmas, e composição farmacêutica
EA201300388A1 (ru) Соединения замещенного бензамида
MX378732B (es) Formas solidas novedosas
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
EA201291095A1 (ru) Способ получения пероральной лекарственной формы, содержащей финголимод
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
FR3012725B1 (fr) Compositions d'agents de lutte biologique, leur procede de preparation et leurs utilisations
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201890532A1 (ru) Новые аннелированные бензамиды
MD4615C1 (ro) Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
MX2017015137A (es) Composicion farmaceutica oral de dosis diaria de isotretinoin.
EA201691160A1 (ru) Антагонисты s1p3
MY174343A (en) Novel heterocyclic compound
BR112016007031A2 (pt) composição farmacêutica oral sólida, processo para a preparação de uma composição farmacêutica, composição farmacêutica bicamada oral sólida, e uso de uma composição farmacêutica
WO2014197536A3 (en) Novel beta lactams as modulators of glutamate uptake and methods for use thereof
TR201717703A2 (tr) Api̇ksaban formülasyonlari
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof
EA201591449A1 (ru) Способы получения противораковых композиций
TR201009166A2 (tr) Sefdinir içeren farmasötik bileşim için üretim yöntemi
TR201902863T4 (tr) Eri̇tropoi̇eti̇n ve seftri̇akson i̇çeren farmasöti̇k bi̇r bi̇leşi̇m ve parki̇nson hastaliği demansinin tedavi̇si̇ i̇çi̇n bi̇r i̇lacin üreti̇lmesi̇nde bunun bi̇r kullanimi.

Legal Events

Date Code Title Description
FG4A Patent for invention issued